Administration of anti-PD-1 antibody in combination with class I HER2-DC1 vaccination increased CD8+ T cell infiltration in tumors (per milligram of tumor) compared to tumor bearing mice that received class I HER2-DC1 only (Figure 7A, p < 0.01). The gene discussed is ERBB2; the disease is neoplasm.